Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.

Abstract

OBJECTIVES:

To report the results of intravitreal ranibizumab injection as primary therapy in aggressive posterior retinopathy of prematurity, the process of the disease, and the additive treatments performed.

METHODS:

This retrospective case review included 15 eyes of 8 premature babies with aggressive posterior retinopathy of prematurity who were initially treated with intravitreal ranibizumab injection. The documented data were gestational age, birth weight, gender, postmenstrual age at intravitreal ranibizumab injection, zone of retinopathy of prematurity, reactivation time of disease, iris neovascularization, retinal hemorrhage, anatomical outcome, and additional treatment.

RESULTS:

Median gestational age at birth was 26 (range, 23-27) weeks, birth weight was 730 (range, 550-970) g, and postconceptional age at aggressive posterior retinopathy of prematurity diagnosis and intravitreal ranibizumab injection was 35 (range, 33-35) weeks. Intravitreal ranibizumab injection was performed as primary treatment. Two eyes necessitated a second intravitreal ranibizumab injection. The reactivation of retinopathy of prematurity was 5 (range, 3-7) weeks after intravitreal ranibizumab injection. Recurrence of the disease in Zone II was treated with laser photocoagulation. A favorable outcome was obtained in all eyes (100%).

CONCLUSION:

Aggressive posterior retinopathy of prematurity is a serious, rapidly progressing form of retinopathy of prematurity that requires quick and proper management. This study indicates that primary treatment with ranibizumab and laser photocoagulation on recurrence provide favorable anatomical outcomes.

• Authors: Nedime Sahinoglu-Keskek, Imren Akkoyun, Birgin Torer
• Journal: European journal of ophthalmology (Eur J Ophthalmol) Vol. 31 Issue 1 Pg. 179-183 (Jan 2021) ISSN: 1724-6016 [Electronic] United States
• PMID: 31718282 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Ranibizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Birth Weight
• Female
• Gestational Age
• Humans
• Infant
• Infant, Extremely Low Birth Weight
• Infant, Newborn
• Infant, Premature
• Intravitreal Injections
• Male
• Ranibizumab (therapeutic use)
• Recurrence
• Retinopathy of Prematurity (diagnosis, drug therapy)
• Retrospective Studies
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)